抗体偶联药物在非小细胞肺癌中的应用

Application of antibody-drug conjugates in the treatment of non-small cell lung cancer

抗体偶联药物(ADC)以其抗体靶向性的独特优势,克服了传统化疗和靶向治疗的局限性,并在肺癌治疗领域取得了突破性的成绩。目前ADC在非小细胞肺癌中的研究主要涉及靶点有HER2、HER3、TROP2、MET、CEACAM5,多种药物已通过严格的临床试验,并表现出良好的安全性和有效性,为肺癌个性化治疗提供了理论依据。

Antibody-drug conjugates(ADCs)have overcome the limitations of traditional chemotherapy and targeted therapy with unique advantage of antibody targeting,and made breakthrough achievements in the treatment of lung cancer.At present,the researches of ADCs in non-small cell lung cancer mainly involve HER2,HER3,TROP2,MET,CEACAM5.Many ADCs have passed rigorous clinical trials,and have shown good safety and efficacy,which provides theoretical basis for individualized treatment of lung cancer.